Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 273-280

  Falagas, Matthew E ^a,b,c   Manta, Katerina G ^a   Ntziora, Fotinie ^a   Vardakas, Konstantinos Z ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Enterococcus; Gram positive; Oxazolidinones; Prosthetic heart valves; Staphylococcus; Streptococcus

Indexed keywords

AMIKACIN; AMPICILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; METICILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ALOPECIA; ANEMIA; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GRAM POSITIVE COCCI; HEART VALVE PROSTHESIS; HUMAN; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PROSTHESIS INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES;

EID: 33748192486     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl219     Document Type: Review

References (41)

1. Moreillon P, Que YA. Infective endocarditis. Lancet 2004; 363: 139-49.
2. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-30.
3. Habib G. Management of infective endocarditis. Heart 2006; 92: 124-30.
4. Hill EE, Herijgers P, Herregods MC et al. Infective endocarditis treated with linezolid: Case report and literature review. Eur J Clin Microbiol Infect Dis 2006; 25: 202-4.
5. Corne P, Marchandin H, Macia JC et al. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37: 946-9.
6. de Feiter PW, Jacobs JA, Jacobs MJ et al. Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens. Scand J Infect Dis 2005; 37: 173-6.
7. Nathani N, Iles P, Elliott TS. Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: A case report. J Infect 2005; 51: E213-5.
8. Ng KH, Lee S, Yip SF et al. A case of Streptococcus mitis endocarditis successfully treated by linezolid. Hong Kong Med J 2005; 11: 411-3.
9. Shah M, Murillo JL. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin. Ann Pharmacother 2005; 39: 1741-4.
10. Souli M, Pontikis K, Chryssouli Z et al. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. Eur J Clin Microbiol Infect Dis 2005; 24: 760-2.
11. Wareham DW, Abbas H, Karcher AM et al. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006; 52: 300-4.
12. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis 2004; 6: 117-9.
13. Bassetti M, Di Biagio A, Del Bono V et al. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Int J Antimicrob Agents 2004; 24: 83-4.
14. Hamza N, Ortiz J, Bonomo RA. Isolated pulmonic valve infective endocarditis: A persistent challenge. Infection 2004; 32: 170-5.
15. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
16. Leung KT, Tong MK, Siu YP et al. Treatment of vancomycin-intermediate Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2004; 36: 483-5.
17. Pistella E, Campanile F, Bongiomo D et al. Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus Endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis 2004; 36: 222-5.
18. Woods CW, Cheng AC, Fowler VG et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 38: 1188-91.
19. Andrade-Baiocchi S, Tognim MC, Baiocchi OC et al. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: Case report and strain characterization. Diagn Microbiol Infect Dis 2003; 45: 149-52.
20. Ang JY, Lua JL, Turner DR et al. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003; 22: 1101-3.
21. Ravindran V, John J, Kaye GC et al. Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J Infect 2003; 47: 164-6.
22. Zimmer SM, Caliendo AM, Thigpen MC et al. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003; 37: E29-30.
23. Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002; 35: 902-4.
24. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: Treatment failure with linezolid. Clin Infect Dis 2002; 35: 1018-20.
25. Viale P, Scolari C, Colombini P et al. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: A case report. J Chemother 2002; 14: 526-9.
26. Babcock HM, Ritchie DJ, Christiansen E et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32: 1373-5.
27. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146-51.
28. Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
29. Dresser LD, Birmingham MC, Karchmer AW et al. Results of treating infective endocarditis with linezolid (LNZ). In: Programs and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 2239, p. 488-9. American Society for Microbiology, Washington, DC, USA.
30. Beloborodova NV, Kuznetsova ST, Vostrikova Tlu et al. Linezolid for the treatment of nosocomial infections after cardiac surgery. Antibiot Khimioter 2003; 48: 11-6.
31. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis 2003; 36: 675-6.
32. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56: 923-9.
33. Nasraway SA, Shorr AF, Kuter DJ et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37: 1609-16.
34. Meissner HC, Townsend T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22: S186-92.
35. Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: Comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-31.
36. Jacqueline C, Asseray N, Batard E et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24: 393-6.
37. Dailey CF, Pagano PJ, Buchanan LV et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2003; 47: 2655-8.
38. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3002-4.
39. Jacqueline C, Batard E, Perez L et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002; 46: 3706-11.
40. Dailey CF, Dileto-Fang CL, Buchanan LV et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2304-8.
41. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: E394-434.